A $900 million print of Junior Subordinated Notes due 2057 by Ameren Corporation (AEE) closed September 18, 2026, generating net proceeds of $891.0 million before expenses. The case for this deal is a large, clean capital raise executed against a shelf registration already in place with the SEC. What complicates the picture is the instrument itself: junior subordinated paper carries the weakest claim among debt holders in a recovery scenario, and the 2057 maturity date extends that obligation across three decades.
Ameren registered the offering under Form S-3 (File No. 333-297949), which the SEC declared effective August 4, 2026. A Prospectus Supplement dated September 8, 2026 governed the specific terms of the notes. The Underwriting Agreement, also dated September 8, 2026, was executed between Ameren and its six bookrunners: Barclays Capital Inc., BofA Securities Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., and Truist Securities Inc. The Bank of New York Mellon Trust Company, N.A. serves as trustee under an indenture dated September 1, 2026.
The 8-K filing attaches two legal opinions. David M. Feinberg, Ameren's Executive Vice President, General Counsel and Secretary, certified the legality of the notes. External counsel Morgan, Lewis & Bockius LLP provided a second opinion.
The counterargument on a transaction of this structure deserves a direct read. Junior subordinated notes sit below every class of senior creditors in the capital structure. Holders absorb losses ahead of senior debt. At $900 million principal and a 31-year maturity, the obligation combines the long-horizon risk of a 2057 instrument with the structural disadvantage of the lowest-ranking debt tier.
On balance, the $891.0 million in net proceeds is what Ameren books before expenses, with the $9 million gap between principal and net reflecting underwriting fees and issuance costs. CFO Leonard P. Singh signed the current report on behalf of the company, incorporated in Missouri and headquartered at 1901 Chouteau Avenue, St. Louis. The line to watch is how Ameren deploys $891.0 million over an instrument that matures in 2057.